



Sample Information

Patient Name: 藍吳麗鈴**Gender:** Female**ID No.:** A224698738**History No.:** 18826534**Age:** 59**Ordering Doctor:** DOC3109L 邱昭華**Ordering REQ.:** C22P5EF**Signing in Date:** 2021/02/24**Path No.:** S110-98262**MP No.:** F21017**Assay:** Oncomine Focus Assay**Sample Type:** FFPE**Block No.:** S108-08399A**Percentage of tumor cells:** 80%**Note:**

Sample Cancer Type: Non-Small Cell Lung Cancer

Table of Contents

Page

Variants (Exclude variant in Taiwan
BioBank with >1% allele frequency)

2

Biomarker Descriptions

2

Relevant Therapy Summary

2

Clinical Trials Summary

3

Report Highlights

1 Relevant Biomarkers

0 Therapies Available

4 Clinical Trials

Relevant Non-Small Cell Lung Cancer Variants

Gene	Finding	Gene	Finding
ALK	Not detected	NTRK1	Not detected
BRAF	Not detected	NTRK2	Not detected
EGFR	Not detected	NTRK3	Not detected
ERBB2	Not detected	RET	Not detected
KRAS	Not detected	ROS1	Not detected
MET	Not detected		

Relevant Biomarkers

Tier	Genomic Alteration	Relevant Therapies (In this cancer type)	Relevant Therapies (In other cancer type)	Clinical Trials
IIC	ERBB3 p.(V104L) c.310G>C erb-b2 receptor tyrosine kinase 3 Allele Frequency: 42.54%	None	None	4

Public data sources included in relevant therapies: FDA1, NCCN, EMA2, ESMO

Tier Reference: Li et al. *Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.* J Mol Diagn. 2017 Jan;19(1):4-23.

Variants (Exclude variant in Taiwan BioBank with >1% allele frequency)

DNA Sequence Variants

Gene	Amino Acid Change	Coding	Variant ID	Locus	Allele Frequency	Transcript	Variant Effect	Coverage
ERBB3	p.(V104L)	c.310G>C	COSM160824	chr12:56478854	42.54%	NM_001982.3	missense	1998

Biomarker Descriptions

ERBB3 (erb-b2 receptor tyrosine kinase 3)

Background: The ERBB3 gene encodes the erb-b2 receptor tyrosine kinase 3, a member of the human epidermal growth factor receptor (HER) family. Along with ERBB3/HER3, EGFR/ERBB1/HER1, ERBB2/HER2, and ERBB4/HER4 make up the HER protein family¹. ERBB3/HER3 binds to extracellular factors, such as neuregulins, but has an impaired kinase domain². Upon ligand binding, ERBB3 forms hetero-dimers with other ERBB/HER family members, including ERBB2/HER2 resulting in activation of tyrosine kinase activity primarily through its dimerization partner.

Alterations and prevalence: ERBB3 gene amplification leading to an increase in expression occurs at low frequency (1-5%) in several cancer types including bladder, esophagus, lung adenocarcinoma, ovarian, pancreas, sarcoma, stomach, and uterine cancers^{3,4,5,6,7,8,9}. ERBB3 is also the target of relatively frequent (5-10%) and recurrent somatic mutations in diverse cancer types including bladder, cervical, colorectal, and stomach cancers^{3,6,8,9,10}. Recurrent ERBB3 mutations such as V104L/M, occur primarily in the extracellular domain.

Potential relevance: Currently, no therapies are approved for ERBB3 aberrations. Overexpression and activation of ERBB3/HER3 is one mechanism of acquired resistance to therapies targeting EGFR and ERBB2/HER2^{11,12}. Preclinical and translational research studies have characterized the oncogenic potential of recurrent ERBB3 mutations and their sensitivity to anti-ERBB antibodies and small molecule inhibitors^{13,14,15,16}. A phase I study exhibited progression-free survival (PFS) of 2.5 months and overall survival (OS) of 9 months in 25 patients with ERBB3 mutations treated by anti-ERBB antibodies or molecular-targeted agents¹⁷.

Relevant Therapy Summary

☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types
 ☒ No evidence

ERBB3 p.(V104L) c.310G>C

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
afatinib	✗	✗	✗	✗	● (II)
BDTX-189	✗	✗	✗	✗	● (I/II)
neratinib, palbociclib, everolimus, trametinib	✗	✗	✗	✗	● (I)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Summary (continued)

☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types
 ☒ No evidence

ERBB3 p.(V104L) c.310G>C (continued)

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
pirotinib	×	×	×	×	<input checked="" type="radio"/> (I)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Clinical Trials Summary

ERBB3 p.(V104L) c.310G>C

NCT ID	Title	Phase
NCT03810872	An Open Explorative Phase II, Open Label Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation	II
NCT04209465	MasterKey-01: A Phase I/II, Open-label, Two-part, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics & Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutations, in Patients w/ Advanced Solid Malignancies	I/II
NCT03065387	Phase I Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib, or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation	I
No NCT ID	Phase I Clinical Study With Advanced Solid Tumors KBP-5209 Treatment	I

Signatures

Testing Personnel:

Laboratory Supervisor:

Pathologist:

References

1. King et al. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. *Science*. 1985 Sep 6;229(4717):974-6. PMID: 2992089
2. Knighton et al. Structural features that specify tyrosine kinase activity deduced from homology modeling of the epidermal growth factor receptor. *Proc. Natl. Acad. Sci. U.S.A.* 1993 Jun 1;90(11):5001-5. PMID: 8389462
3. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. *Nature*. 2014 Mar 20;507(7492):315-22. doi: 10.1038/nature12965. Epub 2014 Jan 29. PMID: 24476821
4. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. *Nature*. 2014 Jul 31;511(7511):543-50. doi: 10.1038/nature13385. Epub 2014 Jul 9. PMID: 25079552
5. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. *Nature*. 2011 Jun 29;474(7353):609-15. PMID: 21720365
6. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature*. 2014 Sep 11;513(7517):202-9. doi: 10.1038/nature13480. Epub 2014 Jul 23. PMID: 25079317
7. Cancer et al. Integrated genomic characterization of endometrial carcinoma. *Nature*. 2013 May 2;497(7447):67-73. PMID: 23636398
8. Weinstein et al. The Cancer Genome Atlas Pan-Cancer analysis project. *Nat. Genet.* 2013 Oct;45(10):1113-20. PMID: 24071849
9. Cerami et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* 2012 May;2(5):401-4. PMID: 22588877
10. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. *Nature*. 2012 Jul 18;487(7407):330-7. PMID: 22810696
11. Mujoo et al. Regulation of ERBB3/HER3 signaling in cancer. *Oncotarget*. 2014 Nov 15;5(21):10222-36. PMID: 25400118
12. Gaborit et al. Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3. *Hum Vaccin Immunother.* 2016 Mar 3;12(3):576-92. PMID: 26529100
13. Mishra et al. Genomic alterations of ERBB receptors in cancer: clinical implications. *Oncotarget*. 2017 Dec 26;8(69):114371-114392. PMID: 29371993
14. Jaiswal et al. Oncogenic ERBB3 mutations in human cancers. *Cancer Cell*. 2013 May 13;23(5):603-17. PMID: 23680147
15. Zhang et al. HER3/ErbB3, an emerging cancer therapeutic target. *Acta Biochim. Biophys. Sin. (Shanghai)*. 2016 Jan;48(1):39-48. PMID: 26496898
16. Ross et al. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3. *Cancer*. 2018 Apr 1;124(7):1358-1373. PMID: 29338072
17. Verlingue et al. Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door. *Eur. J. Cancer*. 2018 Mar;92:1-10. PMID: 29413684